Respiratory Syncytial Virus (RSV)

A common respiratory virus that can cause severe illness in infants and older adults. New vaccines and monoclonal antibodies offer protection.

Disease Burden

RSV is a common respiratory virus that usually causes mild, cold-like symptoms. However, it can be serious for infants and older adults. In the U.S., RSV leads to approximately 58,000-80,000 hospitalizations and 100-300 deaths in children under 5 annually (CDC, 2024).

For adults 65 and older, RSV causes approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths each year. Those at highest risk include premature infants, young children with congenital heart or lung disease, older adults, and people with weakened immune systems.

Vaccines and Prevention

RSV Vaccines (Adults)

  • Arexvy (GSK) - Approved 2023 for 60+
  • Abrysvo (Pfizer) - Approved for 60+ and pregnant women
  • Single dose recommended for adults 75+
  • Adults 60-74 at increased risk should receive

Monoclonal Antibody (Infants)

  • Nirsevimab (Beyfortus) - Approved 2023
  • Single dose for infants under 8 months
  • Recommended for all infants born during RSV season
  • Also for infants 8-19 months at high risk

Related Pages